Search Results - "Dansin, E."

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort by Mazières, J., Barlesi, F., Filleron, T., Besse, B., Monnet, I., Beau-Faller, M., Peters, S., Dansin, E., Früh, M., Pless, M., Rosell, R., Wislez, M., Fournel, P., Westeel, V., Cappuzzo, F., Cortot, A., Moro-Sibilot, D., Milia, J., Gautschi, O.

“…HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1–2% of lung adenocarcinomas. There is, to date, no standard of care…”
Get full text

The future: surgical advances in MEN1 therapeutic approaches and management strategies by Sadowski, S M, Cadiot, G, Dansin, E, Goudet, P, Triponez, F

“…Multiple endocrine neoplasia type 1 (MEN1) is a hereditary autosomal dominant disorder associated with numerous neuroendocrine tumors (NETs). Recent advances…”
Get full text

Méthodes diagnostiques et stratégie thérapeutique des TNE pulmonaires (tumeurs carcinoïdes typiques et atypiques) by Dansin, E.

“…Les carcinoïdes bronchiques typiques ou atypiques sont des tumeurs rares. La prise en charge des formes localisées repose essentiellement sur la chirurgie, et…”
Get full text

Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations by JAMME, P., Escande, F., Descarpentries, C., Copin, M.C., Dansin, E., Vanparis, T., Tulasne, D., Baldacci, S., Kherrouche, Z., Cortot, A.

Get full text

Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France: Final results of the AVANTAGE study by Lionel, F., Perol, D., Souquet, P.-J., Le Caer, H., Dansin, E., Audigier Valette, C., Mouysset, J.-L., Uffredi, M.L., Ionescu-Goga, M., Veerabudun, K., Lelarge, Y., Fabre-Guillevin, E.

Get full text

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort by Thomas, Q.D., Quantin, X., Lemercier, P., Chouaid, C., Schneider, S., Filleron, T., Remon-Masip, J., Perol, M., Debieuvre, D., Audigier-Valette, C., Justeau, G., Loeb, A., Hiret, S., Clement-Duchene, C., Dansin, E., Stancu, A., Pichon, E., Bosquet, L., Girard, N., Du Rusquec, P.

“…The RAS/MEK signaling pathway is essential in carcinogenesis and frequently altered in non-small-cell lung cancer (NSCLC), notably by KRAS mutations (KRASm)…”
Get full text

3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience by Cadranel, J, Cortot, A, Lena, H, Mennecier, B, Do, P, Dansin, E, Mazieres, J, Chouaid, C, Perol, M, Barlesi, F

Get full text

MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer by Baldacci, S, Kherrouche, Z, Descarpentries, C, Wislez, M, Dansin, E, Furlan, A, Tulasne, D, Cortot, A B

“…The mutations leading to MET exon 14 skipping represent a new class of molecular alterations described in various cancers. These alterations are observed in 2…”
Get more information

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences by Montagne, R, Berbon, M, Doublet, L, Debreuck, N, Baranzelli, A, Drobecq, H, Leroy, C, Delhem, N, Porte, H, Copin, M-C, Dansin, E, Furlan, A, Tulasne, D

“…Upon activation by its ligand hepatocyte growth factor/scatter factor, the receptor tyrosine kinase Met promotes survival, proliferation, and migration of…”
Get full text

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 by BORGET, I, CADRANEL, J, DANIEL, C, MORIN, F, CHOUAID, C, PIGNON, J.-P, QUOIX, E, COUDERT, B, WESTEEL, V, DANSIN, E, MADELAINE, J, MADROSZYK, A, FRIARD, S

“…Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but…”
Get full text

3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort by Cadranel, J, Quoix, E, Duruisseaux, M, Friard, S, Fabre, E, Daniel, C, Westeel, V, Madroszyk, A, Lena, H, Merle, P, Mazieres, J, Dansin, E, Scherpereel, A, Hiret, S, Coudert, B, Souquet, P.J, Missy, P, Morin, F, Zalcman, G, Barlesi, F

Get full text

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer by Krzakowski, M., Bennouna, J., Dansin, E., Kowalski, D., Hiret, S., Penel, N., Favrel, S., Tourani, J. M.

“…Background Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have…”
Get full text

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care by Penel, N, Clisant, S, Dansin, E, Desauw, C, Dégardin, M, Mortier, L, Vanhuyse, M, Bonodeau, F, Fournier, C, Cazin, J-L, Adenis, A

“…Background: To evaluate the antitumour activity and safety of metronomic cyclophosphamide vs megestrol acetate in progressive and advanced cancer patients…”
Get full text

Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study by Fontaine-Delaruelle, C., Mazières, J., Cadranel, J., Mastroianni, B., Dubos-Arvis, C., Dumont, P., Monnet, I., Pichon, E., Locatelli-Sanchez, M., Dixmier, A., Coudert, B., Fraboulet, S., Foucher, P., Dansin, E., Baize, N., Vincent, M., Missy, P., Morin, F., Moro-Sibilot, D., Couraud, S.

“…Lung cancer in women is on the rise, with a higher proportion occurring in lifelong never-smokers. Lung cancer in never-smokers (LCINS) exhibits a high…”
Get full text

Reflections on the limits of specific treatments in thoracic oncology by Dansin, E, Lauridant, G, Reich, M, Villet, S, Fournel, P

“…The modest impact of specific treatments is a major problem in oncology and particularly for metastatic lung cancer patients. Therapeutic progress achieved by…”
Get more information

Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors by Barlési, F., Balleyguier, C., Besse, B., Bonodeau, F., Brenac, F., Corneloup, O., Dansin, E., Ferretti, G., Gaubert, J.Y., Gervais, R., Lacombe, C., Loundou, A., Moro-Sibilot, D., Planchard, D., Scherpereel, A., Menu, Y.

“…Bevacizumab (BVZ) combined with platinum-based therapy is registered for first-line treatment of nonsquamous non-small-cell lung cancer (NSCLC). Patients with…”
Get full text

75P STEREOTACTIC RADIOTHERAPY FOR LUNG CANCER: EARLY EFFICACY AND TOXICITY EVALUATION OF A NON-INVASIVE REAL-TIME TUMOR TRACKING SYSTEM by Bibault, J, Prevost, B, Dansin, E, Mirabel, X, Lacornerie, T, Dubus, F, Lartigau, E

Get full text

Anti-Hu antibody syndrome: diagnostic and therapeutic difficulties by Leroy, T, Porte, H, Rousselot, C, Taieb, S, Outteryck, O, Dansin, É

“…Anti-Hu antibody syndrome is a paraneoplastic syndrome usually associated with small cell lung carcinoma which induces various symptoms, particularly…”
Get more information

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma by Ferté, C., Besse, B., Dansin, E., Parent, F., Buisine, M.-P., Copin, M.-C., Penel, N., Soria, J.-C.

Get full text

Information on head, neck and lung cancers by Dansin, E, Lefebvre, J-L

“…Notable advances have been achieved in head and neck cancer and in lung cancer as regards oncogenesis knowledge and treatment optimization. Multimodal…”
Get more information